目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 36)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MOLECULAR DIAGNOSTICS MARKET: MARKET SEGMENTATION
1.3.2 MOLECULAR DIAGNOSTICS INDUSTRY: GEOGRAPHICAL SEGMENTATION
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 MARKET LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 42)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Company presentations and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
2.9 RISK ASSESSMENT
2.9.1 RISK ASSESSMENT OF MARKET
2.10 IMPACT OF ECONOMIC RECESSION ON MARKET

3 EXECUTIVE SUMMARY (Page No. - 57)
FIGURE 8 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 MOLECULAR DIAGNOSTICS INDUSTRY, BY TEST TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 10 MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 14 MOLECULAR DIAGNOSTICS INDUSTRY, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 63)
4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
FIGURE 15 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND RISING INCIDENCE OF CANCER TO SUPPORT MARKET
4.2 MOLECULAR DIAGNOSTICS INDUSTRY, BY PRODUCT & SERVICE, 2023 VS. 2028
FIGURE 16 REAGENTS & KITS TO DOMINATE MARKET IN 2028
4.3 MARKET, BY TEST TYPE, 2023 VS. 2028
FIGURE 17 LAB TESTS TO COMMAND GREATER MARKET SHARE IN 2028
4.4 MARKET, BY SAMPLE TYPE, 2023 VS. 2028
FIGURE 18 BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD
4.5 MARKET, BY TECHNOLOGY, 2023 VS. 2028
FIGURE 19 PCR SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.6 MARKET, BY APPLICATION, 2023 VS. 2028
FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2028
4.7 MARKET, BY END USER, 2023 VS. 2028
FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.8 MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MARKET DURING STUDY PERIOD

5 MARKET OVERVIEW (Page No. - 68)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of infectious diseases and cancer globally
TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025
TABLE 2 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025
5.2.1.2 Rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies
5.2.1.3 Growing awareness regarding early disease diagnosis in developing countries
5.2.1.4 Rising technological advancements in molecular diagnostics in recent years
5.2.1.5 Increasing use of PoC diagnostic tests in homecare settings and hospitals
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
5.2.2.2 High cost of molecular diagnostic instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Growing significance of companion diagnostics in drug development process
5.2.3.2 Increasing growth opportunities for molecular diagnostics companies in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape for IVD and molecular diagnostics in US and European Union
5.2.4.2 Operational barriers and shortage of skills across major markets
5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis
5.3 PRICING ANALYSIS
5.3.1 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS PRODUCTS, BY KEY PLAYER
TABLE 3 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS
5.4 PATENT ANALYSIS
FIGURE 24 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013-DECEMBER 2022)
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS OF MOLECULAR DIAGNOSTICS INDUSTRY: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 26 MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM/MARKET MAP ANALYSIS
FIGURE 27 MARKET: ECOSYSTEM/MARKET MAP ANALYSIS
5.7.1 MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT FROM NEW ENTRANTS
5.8.2 THREAT FROM SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY ANALYSIS
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.1 NORTH AMERICA
5.9.1.1 US
5.9.1.2 Canada
5.9.2 EUROPE
TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
5.9.3 ASIA PACIFIC
5.9.3.1 China
5.9.3.2 Japan
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.9.3.3 India
5.9.4 LATIN AMERICA
5.9.4.1 Brazil
5.9.4.2 Mexico
5.9.5 MIDDLE EAST
5.9.6 AFRICA
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2023-2024
TABLE 11 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023-2024
5.13 PESTLE ANALYSIS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14.1 REVENUE SHIFT IN MARKET
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS (%)
5.15.2 BUYING CRITERIA
FIGURE 29 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
TABLE 13 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
5.16 CASE STUDY ANALYSIS
FIGURE 30 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA

6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 99)
6.1 INTRODUCTION
TABLE 14 MOLECULAR DIAGNOSTICS INDUSTRY, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 15 PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022)
6.2 REAGENTS & KITS
6.2.1 RECURRENT PURCHASES OF REAGENTS & KITS FOR DIAGNOSTIC ANALYSIS TO PROPEL MARKET
TABLE 16 MARKET FOR REAGENTS & KITS, BY REGION, 2021-2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
TABLE 17 KEY INSTRUMENTS AVAILABLE IN GLOBAL MARKET
TABLE 18 MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)
6.4 SERVICES & SOFTWARE
6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS IN MARKET TO DRIVE GROWTH
TABLE 19 MARKET FOR SERVICES & SOFTWARE, BY REGION, 2021-2028 (USD MILLION)

7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE (Page No. - 105)
7.1 INTRODUCTION
TABLE 20 MOLECULAR DIAGNOSTICS INDUSTRY, BY TEST TYPE, 2021-2028 (USD MILLION)
7.1.1 PRIMARY NOTES
7.1.1.1 Key industry insights
7.2 LAB TESTS
7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
TABLE 21 MARKET FOR LAB TESTS, BY REGION, 2021-2028 (USD MILLION)
7.3 POC TESTS
7.3.1 FASTER TURNAROUND TIME OF POC TESTS TO DRIVE SEGMENT GROWTH
TABLE 22 MARKET FOR POC TESTS, BY REGION, 2021-2028 (USD MILLION)

8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE (Page No. - 110)
8.1 INTRODUCTION
TABLE 23 MOLECULAR DIAGNOSTICS INDUSTRY, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
8.2 BLOOD, SERUM, AND PLASMA
8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 24 MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021-2028 (USD MILLION)
8.3 URINE
8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH
TABLE 25 MARKET FOR URINE, BY REGION, 2021-2028 (USD MILLION)
8.4 OTHER SAMPLE TYPES
TABLE 26 MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021-2028 (USD MILLION)

9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 114)
9.1 INTRODUCTION
9.1.1 PRIMARY NOTES
9.1.1.1 Key industry insights
TABLE 27 MOLECULAR DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2021-2028 (USD MILLION)
9.2 POLYMERASE CHAIN REACTION
9.2.1 GROWING USE OF POLYMERASE CHAIN REACTION IN PROTEOMICS AND GENOMICS TO DRIVE MARKET
TABLE 28 MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021-2028 (USD MILLION)
9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
9.3.1 COST BENEFITS OF ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY IN NUCLEIC ACID SEQUENCING TO DRIVE MARKET
TABLE 29 MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021-2028 (USD MILLION)
9.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
9.4.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET
TABLE 30 MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021-2028 (USD MILLION)
9.5 IN SITU HYBRIDIZATION
9.5.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
TABLE 31 MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)
9.6 DNA MICROARRAYS
9.6.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS
TABLE 32 MARKET FOR DNA MICROARRAYS, BY REGION, 2021-2028 (USD MILLION)
9.7 OTHER TECHNOLOGIES
TABLE 33 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)

10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 123)
10.1 INTRODUCTION
TABLE 34 MOLECULAR DIAGNOSTICS INDUSTRY, BY APPLICATION, 2021-2028 (USD MILLION)
10.2 INFECTIOUS DISEASE DIAGNOSTICS
TABLE 35 MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
TABLE 36 MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
10.2.1 HEPATITIS
10.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive segment
TABLE 37 HEPATITIS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 38 HEPATITIS MARKET, BY REGION, 2021-2028 (MILLION TESTS)
10.2.2 HIV
10.2.2.1 Increased global prevalence of HIV to propel segment
TABLE 39 HIV MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 40 HIV MARKET, BY REGION, 2021-2028 (MILLION TESTS)
10.2.3 CT/NG
10.2.3.1 CT/NG infections to be most common sexually transmitted disease globally
TABLE 41 CT/NG MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 42 CT/NG MARKET, BY REGION, 2021-2028 (MILLION TESTS)
10.2.4 HAIS
10.2.4.1 Rising burden of MRSA infections and increasing adoption of technologically advanced HAI diagnostic tests to aid market
TABLE 43 HAIS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 44 HAIS MARKET, BY REGION, 2021-2028 (MILLION TESTS)
10.2.5 HPV
10.2.5.1 Technological advancements for preventing HPV infections to augment market
TABLE 45 HPV MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 46 HPV MARKET, BY REGION, 2021-2028 (MILLION TESTS)
10.2.6 TUBERCULOSIS
10.2.6.1 Increasing burden of TB globally to propel market
TABLE 47 TUBERCULOSIS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 48 TUBERCULOSIS MARKET, BY REGION, 2021-2028 (MILLION TESTS)
10.2.7 INFLUENZA
10.2.7.1 Rising focus on decreasing spread of influenza to propel segment
TABLE 49 INFLUENZA MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 50 INFLUENZA MARKET, BY REGION, 2021-2028 (MILLION TESTS)
10.2.8 OTHER INFECTIOUS DISEASES
TABLE 51 OTHER INFECTIOUS DISEASES MARKET, BY REGION, 2021-2028 (USD MILLION)
10.3 ONCOLOGY TESTING
TABLE 52 MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 53 MARKET FOR ONCOLOGY TESTING, BY REGION, 2021-2028 (USD MILLION)
10.3.1 BREAST CANCER
10.3.1.1 Increasing prevalence of breast cancer among females to boost market
TABLE 54 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 55 BREAST CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)
10.3.2 COLORECTAL CANCER
10.3.2.1 Rising focus on development of companion diagnostic assays to fuel market
TABLE 56 COLORECTAL CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)
10.3.3 LUNG CANCER
10.3.3.1 Increasing research for lung cancer biomarkers to drive market
TABLE 57 LUNG CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)
10.3.4 PROSTATE CANCER
10.3.4.1 Advancements in genomic technologies for development of new biomarkers to aid market
TABLE 58 PROSTATE CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)
10.3.5 OTHER CANCERS
TABLE 59 GLOBAL CANCER INCIDENCE, 2020
TABLE 60 OTHER CANCERS MARKET, BY REGION, 2021-2028 (USD MILLION)
10.4 GENETIC TESTING
10.4.1 DIAGNOSIS OF VARIOUS DISEASES THROUGH GENETIC TESTING METHODS TO PROPEL MARKET
TABLE 61 MARKET FOR GENETIC TESTING, BY REGION, 2021-2028 (USD MILLION)
10.5 OTHER APPLICATIONS
TABLE 62 MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
10.6 COVID-19
10.6.1 DECLINING CASES OF COVID-19 TO HINDER MARKET
TABLE 63 MARKET FOR COVID-19, BY REGION, 2021-2028 (USD MILLION)

11 MOLECULAR DIAGNOSTICS MARKET, BY END USER (Page No. - 144)
11.1 INTRODUCTION
TABLE 64 MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
11.2 DIAGNOSTIC LABORATORIES
11.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET
TABLE 65 MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
11.3 HOSPITALS & CLINICS
11.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT
TABLE 66 MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021-2028 (USD MILLION)
11.4 OTHER END USERS
TABLE 67 MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

12 MOLECULAR DIAGNOSTICS MARKET, BY REGION (Page No. - 149)
12.1 INTRODUCTION
TABLE 68 MOLECULAR DIAGNOSTICS INDUSTRY, BY REGION, 2021-2028 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 31 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 69 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 70 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 71 NORTH AMERICA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 72 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 73 NORTH AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 74 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 75 NORTH AMERICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 76 NORTH AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA
12.2.2 US
12.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
TABLE 77 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 78 US: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 79 US: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 80 US: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 81 US: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 82 US: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.2.3 CANADA
12.2.3.1 High availability of funding for genomics research to fuel market
TABLE 83 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 84 CANADA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 85 CANADA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 86 CANADA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 87 CANADA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 88 CANADA: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
12.3 EUROPE
TABLE 89 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 90 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 91 EUROPE: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 92 EUROPE: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 93 EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 94 EUROPE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 95 EUROPE: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 96 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE
12.3.2 GERMANY
12.3.2.1 Increasing healthcare expenditure with favorable government policies and rising per capita disposable income to propel market
TABLE 97 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 98 GERMANY: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 99 GERMANY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 100 GERMANY: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 101 GERMANY: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 102 GERMANY: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.3 UK
12.3.3.1 Growing number of accredited diagnostic laboratories to fuel market
TABLE 103 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 104 UK: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 105 UK: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 106 UK: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 107 UK: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 108 UK: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
12.3.4 FRANCE
12.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market
TABLE 109 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 110 FRANCE: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 111 FRANCE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 112 FRANCE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 113 FRANCE: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 114 FRANCE: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.5 ITALY
12.3.5.1 Adoption of advanced diagnostic technologies to support market
TABLE 115 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 116 ITALY: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 117 ITALY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 118 ITALY: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 119 ITALY: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 120 ITALY: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.6 SPAIN
12.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
TABLE 121 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 122 SPAIN: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 123 SPAIN: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 124 SPAIN: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 125 SPAIN: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 126 SPAIN: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
12.3.7 RUSSIA
12.3.7.1 Increasing access to quality healthcare and growing incidence of infectious diseases to aid market
TABLE 127 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 128 RUSSIA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 129 RUSSIA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 130 RUSSIA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 131 RUSSIA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 132 RUSSIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.8 REST OF EUROPE
TABLE 133 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 134 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 135 REST OF EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 136 REST OF EUROPE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 137 REST OF EUROPE: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 138 REST OF EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4 ASIA PACIFIC
FIGURE 32 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 139 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 140 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 141 ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 142 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 143 ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 144 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 145 ASIA PACIFIC: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 146 ASIA PACIFIC: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
12.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Rapid economic growth and greater public access to modern healthcare to drive market
TABLE 147 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 148 CHINA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 149 CHINA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 150 CHINA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 151 CHINA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 152 CHINA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.3 JAPAN
12.4.3.1 Universal healthcare reimbursement policy to support market
TABLE 153 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 154 JAPAN: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 155 JAPAN: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 156 JAPAN: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 157 JAPAN: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 158 JAPAN: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.4 INDIA
12.4.4.1 Increased private & public investments and large patient population to drive market
TABLE 159 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 160 INDIA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 161 INDIA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 162 INDIA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 163 INDIA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 164 INDIA: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
12.4.5 AUSTRALIA
12.4.5.1 High prevalence of infectious diseases to fuel market
TABLE 165 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 166 AUSTRALIA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 167 AUSTRALIA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 168 AUSTRALIA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 169 AUSTRALIA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 170 AUSTRALIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.6 REST OF ASIA PACIFIC
TABLE 171 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 172 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 173 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 174 REST OF ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.5 LATIN AMERICA
TABLE 177 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 178 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 179 LATIN AMERICA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 180 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 181 LATIN AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 182 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 183 LATIN AMERICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 184 LATIN AMERICA: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
12.5.1 IMPACT OF ECONOMIC RECESSION ON LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Improving healthcare infrastructure and stringent regulations to fuel market
TABLE 185 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 186 BRAZIL: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 187 BRAZIL: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 188 BRAZIL: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 189 BRAZIL: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 190 BRAZIL: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.5.3 MEXICO
12.5.3.1 Improving accessibility and affordability of healthcare services to aid market
TABLE 191 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 192 MEXICO: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 193 MEXICO: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 194 MEXICO: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 195 MEXICO: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 196 MEXICO: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.5.4 REST OF LATIN AMERICA
TABLE 197 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 198 REST OF LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 199 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 200 REST OF LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 201 REST OF LATIN AMERICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 202 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
12.6 MIDDLE EAST & AFRICA
12.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET
TABLE 203 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 204 MIDDLE EAST & AFRICA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 205 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 206 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 207 MIDDLE EAST & AFRICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 208 MIDDLE EAST & AFRICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 209 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.6.2 IMPACT OF ECONOMIC RECESSION ON MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE (Page No. - 227)
13.1 OVERVIEW
13.2 STRATEGIES ADOPTED BY KEY PLAYERS
13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
TABLE 210 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR DIAGNOSTIC MANUFACTURING COMPANIES
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 33 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MOLECULAR DIAGNOSTICS INDUSTRY
13.4 MARKET SHARE ANALYSIS
FIGURE 34 MARKET SHARE, BY KEY PLAYER (2022)
TABLE 211 MARKET: DEGREE OF COMPETITION
13.4.1 MARKET SHARE AND RANKING ANALYSIS, BY TECHNOLOGY
13.4.1.1 Polymerase chain reaction (PCR)
FIGURE 35 GLOBAL MARKET SHARE FOR PCR, BY KEY PLAYER (2022)
13.4.1.2 DNA sequencing and NGS
FIGURE 36 GLOBAL MARKET SHARE FOR DNA SEQUENCING & NGS, BY KEY PLAYER (2022)
13.4.1.3 Isothermal nucleic acid amplification technology (INAAT)
TABLE 212 GLOBAL MARKET RANKING FOR INAAT, BY KEY PLAYER, 2022
13.4.1.4 In situ hybridization (ISH)
TABLE 213 GLOBAL MARKET RANKING FOR ISH, BY KEY PLAYER, 2022
13.4.2 MARKET RANKING ANALYSIS, BY APPLICATION
13.4.2.1 Infectious diseases
TABLE 214 GLOBAL MARKET RANKING FOR INFECTIOUS DISEASES, BY KEY PLAYER, 2022
13.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
13.5.1 LIST OF EVALUATED VENDORS
13.5.2 STARS
13.5.3 EMERGING LEADERS
13.5.4 PERVASIVE PLAYERS
13.5.5 PARTICIPANTS
FIGURE 37 MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
13.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022)
13.6.1 PROGRESSIVE COMPANIES
13.6.2 STARTING BLOCKS
13.6.3 RESPONSIVE COMPANIES
13.6.4 DYNAMIC COMPANIES
FIGURE 38 MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
13.7 COMPETITIVE BENCHMARKING
13.7.1 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS
FIGURE 39 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN MOLECULAR DIAGNOSTICS INDUSTRY
TABLE 215 MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 216 COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 217 COMPANY REGIONAL FOOTPRINT
TABLE 218 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
13.8 COMPETITIVE SCENARIO
13.8.1 KEY PRODUCT LAUNCHES
TABLE 219 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
13.8.2 KEY DEALS
TABLE 220 KEY DEALS

14 COMPANY PROFILES (Page No. - 243)
14.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 221 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
14.1.2 HOLOGIC, INC.
TABLE 222 HOLOGIC, INC.: COMPANY OVERVIEW
FIGURE 41 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
14.1.3 ABBOTT LABORATORIES
TABLE 223 ABBOTT LABORATORIES: COMPANY OVERVIEW
FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
14.1.4 BIOMÉRIEUX
TABLE 224 BIOMÉRIEUX: COMPANY OVERVIEW
FIGURE 43 BIOMÉRIEUX: COMPANY SNAPSHOT (2022)
14.1.5 THERMO FISHER SCIENTIFIC INC.
TABLE 225 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
14.1.6 QIAGEN
TABLE 226 QIAGEN: COMPANY OVERVIEW
FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2022)
14.1.7 PERKINELMER INC.
TABLE 227 PERKINELMER INC.: COMPANY OVERVIEW
FIGURE 46 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
14.1.8 MYRIAD GENETICS, INC.
TABLE 228 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022)
14.1.9 SIEMENS HEALTHINEERS AG
TABLE 229 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
14.1.10 DANAHER
TABLE 230 DANAHER: COMPANY OVERVIEW
FIGURE 49 DANAHER: COMPANY SNAPSHOT (2022)
14.2 OTHER PLAYERS
14.2.1 ILLUMINA, INC.
14.2.2 BECTON, DICKINSON AND COMPANY
14.2.3 GRIFOLS, S.A.
14.2.4 QUIDELORTHO CORPORATION
14.2.5 AGILENT TECHNOLOGIES, INC.
14.2.6 DIASORIN S.P.A.
14.2.7 EXACT SCIENCES CORPORATION
14.2.8 GENETIC SIGNATURES
14.2.9 MDXHEALTH
14.2.10 HTG MOLECULAR DIAGNOSTICS, INC.
14.2.11 BIOCARTIS
14.2.12 TBG DIAGNOSTICS LIMITED
TABLE 231 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
14.2.13 VELA DIAGNOSTICS
TABLE 232 VELA DIAGNOSTICS: COMPANY OVERVIEW
14.2.14 AMOY DIAGNOSTICS CO., LTD.
TABLE 233 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
14.2.15 ELITECHGROUP
TABLE 234 ELITECHGROUP: COMPANY OVERVIEW
14.2.16 MOLBIO DIAGNOSTICS PVT. LTD.
TABLE 235 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
14.2.17 SAVYON DIAGNOSTICS
TABLE 236 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
14.2.18 ABACUS DIAGNOSTICA OY
TABLE 237 ABACUS DIAGNOSTICA OY.: COMPANY OVERVIEW
14.2.19 GENEOMBIO TECHNOLOGIES PVT. LTD.
TABLE 238 GENEOMBIO TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX (Page No. - 311)
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS